AZR — ADIAL PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1513525 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 58,000 | 0 | -52,025,000 | -51,989,000 | 29,089,000 | — | 28,933,000 |
| Mar 2026 | 47,059 | 0 | -2,001,481 | -2,022,392 | 5,227,321 | — | 1,510,071 |
| Sep 2025 | 47,860 | 0 | -1,764,078 | -1,793,651 | 5,659,847 | 4,606,289 | 1,154,756 |
| Jun 2025 | 23,747 | 0 | -1,882,712 | -1,958,556 | 6,801,703 | 5,914,980 | 1,211,027 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-143,984,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-57,675,938
Pretax Income TTM
$-57,801,206
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 8y)
Revenues vs Net Income (last 8y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 149,567 | -7,799,462 | -7,977,171 | 6,673,367 | 1,396,909 | 5,276,458 | — |
| Dec 2024 | 178,659 | -8,284,457 | -13,197,451 | 5,043,942 | 975,858 | 4,068,084 | — |
| Dec 2023 | 69,779 | -6,887,947 | -5,123,341 | 4,736,605 | 653,076 | 4,083,529 | — |
| Dec 2022 | 63,209 | -13,317,127 | -12,731,416 | 5,732,804 | 2,456,310 | 3,276,494 | — |
| Dec 2021 | 6,539 | -19,288,723 | -19,423,326 | 7,474,975 | 3,967,164 | 3,507,811 | — |
| Dec 2020 | 32,495 | -10,927,985 | -10,892,990 | 5,491,444 | 1,505,378 | 3,986,066 | — |
| Dec 2019 | 95,234 | -8,244,900 | -8,591,429 | 7,679,637 | 539,051 | 7,140,586 | — |
| Dec 2018 | 7,392 | -6,987,222 | -11,631,378 | 4,699,285 | 257,974 | 4,441,311 | — |
TTM Snapshot
Revenues TTM
$195,533
NetIncome TTM
$-57,801,206
OpCashFlow TTM
—
Assets (Latest)
$29,089,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1417.54 | — |
| JNJ | JOHNSON & JOHNSON | $657.68B | $273.20 | — |
| ABBV | AbbVie Inc. | $521.11B | $294.89 | — |
| MRK | Merck & Co., Inc. | $368.89B | $149.52 | — |
| NVS | NOVARTIS AG | $305.62B | $160.79 | — |
News headlines (Yahoo Finance, 1h cache)
Recent Insider Activity
No insider activity indexed for this ticker.